Global Market: European shares rebound as tech stocks recover; investors assess Middle East developments
European stock markets traded higher on Thursday, recovering from previous losses. Technology shares led the gains, driven by renewed interest in artificial intelligence demand. Oil prices eased despite ongoing geopolitical uncertainty in the Midd...

The pan-European STOXX 600 index rose 0.4% to 638.66 in early trading, recovering part of the sharp losses recorded in the previous session. According to Reuters, market sentiment improved after U.S. President Donald Trump indicated that Iran wanted to negotiate, easing some concerns over an escalation in the regional conflict.
Technology stocks lead gains
Technology stocks emerged as the top-performing sector, climbing 1.6% after a recent pullback. The sector had delivered its strongest quarterly performance since 2001 in June but had come under pressure this month as investors questioned elevated valuations.
Chipmakers spearheaded Thursday's advance, with Germany-based Siltronic surging 7.4%, France's Soitec gaining 5.5%, and Dutch semiconductor equipment giant ASML rising 2.5%.
Reuters reported that investor sentiment also received a boost from reports suggesting China could permit domestic artificial intelligence companies limited access to Nvidia's H200 chips, potentially supporting further investment in AI infrastructure.
Crude oil prices edged lower as investors monitored the evolving situation in the Middle East. Oil remains a critical input for Europe's largely energy-importing economies, making price movements closely watched by equity investors.
According to Reuters, markets continued to assess the implications of the latest U.S. military strikes on Iran, which followed President Trump's declaration that negotiations with Tehran had ended. The geopolitical tensions had triggered the STOXX 600's biggest one-day decline since March in the previous session.
Spanish equities outperform
Spain's benchmark equity index outperformed regional peers, rising 0.9% after hitting a three-week low on Wednesday.
AstraZeneca tumbles after trial setback
Healthcare stocks faced pressure after AstraZeneca fell 8%.
The decline came after Reuters reported that the pharmaceutical company's nerve disease treatment Wainua, developed in partnership with U.S.-based Ionis Pharmaceuticals, failed to achieve the primary objective of reducing cardiovascular deaths and recurrent heart complications in a late-stage clinical trial.
Market outlook
European equities remain highly sensitive to geopolitical headlines, energy price movements and developments surrounding artificial intelligence spending. While Thursday's recovery in technology shares provided support to broader markets, investors are likely to remain cautious as they monitor the Middle East situation, global trade developments and corporate earnings for further direction.
Download ET Markets APP